Researchers identify important adenovirus receptor in macrophages of mice

Scientists demonstrate how adenovirus invades the immune system of mice

Adenoviral infections have a mild disease progression in healthy people, but it can be dangerous for immunocompromised people. If a patient is infected with the virus and gets a bacterial infection on top of it, it can lead to an excessive inflammatory response known as a cytokine storm, an overreaction by the immune system leading to high concentrations of proteins that promote inflammation. Many patients do not survive this crisis. Mareike Maler from the University Hospital Freiburg, Prof. Dr. Marina Freudenberg from the Department of Pneumology at the University Hospital Freiburg and the BIOSS Centre for Biological Signalling Studies, Dr. György Fejer from the University of Plymouth, England along with Prof. Dr. Wolfgang Schamel from the Department of Biology and the BIOSS Centre for Biological Signaling Studies have now identified an important adenovirus receptor in macrophages of mice. The receptor "MARCO" enables the adenoviruses to invade macrophages, important immune cells responsible for detecting and destroying pathogens. The findings of this study, in which immunologists from the MPI of Immunobiology and Epigenetics Freiburg, RWTH Aachen and the University of Zurich, Switzerland were also involved, have recently been published in the scientific journal mBio.

Previous studies with epithelial cells from skin and gland tissue showed that the viruses bind to the cell-surface proteins called integrins and to CAR, the receptor for coxsackievirus and adenovirus. Biologists have been searching for the adenovirus receptor in immune cells since the 1990s. The research in Freiburg sought to clarify how adenoviruses attack cells of the immune system; that is, on which receptors the viruses on the cellular surface land, in order to invade the cell. The clarification of this question is of particular interest because the pharmaceutical industry has recently shown interest in using adenoviruses in gene therapy to channel genetic information into human cells. During the first clinical trials, however, some patients showed symptoms of a cytokine storm, suggesting that they may have contracted a bacterial infection.

Up to now, the scavenger receptor MARCO was viewed mainly as a so-called pattern recognition receptor with which the macrophage recognizes bacteria. However, the new findings prove that the receptor has an additional function in fighting viral pathogens. MARCO is probably fundamental for activating macrophages, for instance, in order to produce inflammation-promoting cytokines. In addition, the researchers demonstrate that macrophages derived from bone marrow precursor cells are far less infected with the virus than the macrophages in the lung. The reason for this is partly because the bone marrow macrophages usually lack MARCO and therefore cannot effectively be attacked by the virus.

After the discovery of these scientific findings, it is now time to conduct testing on humans. Although the receptor MARCO is also found in humans, it is still not clear if the virus interacts with the same receptor in humans. Nonetheless, the study has provided information on how macrophages fight viruses and that they have the potential to activate a cytokine storm in humans. In the future, medication could be used to block the receptor MARCO, thereby avoiding the cytokine storm.​

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
More than half of all US adults are eligible for semaglutide therapy